A new combination treatment eliminating many of the side effects of traditional chemotherapy for mantle cell lymphoma has shown favorable response in a two-year trial according to Weill Cornell Medicine research. The pill Lenalidomide, taken in combination with the antibody Rituximab shrunk tumor size by more than more than half in 90% of the patients enrolled in a small efficacy clinical trial. And, more than two-thirds of the group had no evidence of a detectable tumor after treatment completed. Long-term outcomes found that patients were able to resume their daily lifestyle with a higher quality of life while undergoing treatment. You can read more about this exciting research and the findings published in the New England Journal of Medicine by clicking here.